• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rev Med Virol Comparison of Confirmed COVID-19 With SARS and MERS Cases - Clinical Characteristics, Laboratory Findings, Radiographic Signs and Outc

tetano

Editor, Senior Moderator
Rev Med Virol


. 2020 Jun 5;e2112.
doi: 10.1002/rmv.2112. Online ahead of print.
Comparison of Confirmed COVID-19 With SARS and MERS Cases - Clinical Characteristics, Laboratory Findings, Radiographic Signs and Outcomes: A Systematic Review and Meta-Analysis


Ali Pormohammad[SUP] 1 [/SUP], Saied Ghorbani[SUP] 2 [/SUP], Alireza Khatami[SUP] 2 [/SUP], Rana Farzi[SUP] 3 [/SUP], Behzad Baradaran[SUP] 4 5 [/SUP], Diana L Turner[SUP] 6 [/SUP], Raymond J Turner[SUP] 7 [/SUP], Nathan C Bahr[SUP] 8 [/SUP], Juan-Pablo Idrovo[SUP] 9 [/SUP]



Affiliations

Abstract

Introduction: Within this large-scale study, we compared clinical symptoms, laboratory findings, radiographic signs, and outcomes of COVID-19, SARS, and MERS to find unique features.
Method: We searched all relevant literature published up to February 28, 2020. Depending on the heterogeneity test, we used either random or fixed-effect models to analyze the appropriateness of the pooled results. Study has been registered in the PROSPERO database (ID 176106).
Result: Overall 114 articles included in this study; 52 251 COVID-19 confirmed patients (20 studies), 10 037 SARS (51 studies), and 8139 MERS patients (43 studies) were included. The most common symptom was fever; COVID-19 (85.6%, P < .001), SARS (96%, P < .001), and MERS (74%, P < .001), respectively. Analysis showed that 84% of Covid-19 patients, 86% of SARS patients, and 74.7% of MERS patients had an abnormal chest X-ray. The mortality rate in COVID-19 (5.6%, P < .001) was lower than SARS (13%, P < .001) and MERS (35%, P < .001) between all confirmed patients.
Conclusions: At the time of submission, the mortality rate in COVID-19 confirmed cases is lower than in SARS- and MERS-infected patients. Clinical outcomes and findings would be biased by reporting only confirmed cases, and this should be considered when interpreting the data.

Keywords: COVID-19; Middle East respiratory syndrome coronavirus; SARS virus; coronavirus; meta-analysis; severe acute respiratory syndrome.
 
Back
Top Bottom